


In the Claims

1. (Original) An enhancing agent for enhancing therapeutic or prophylactic effect of administering (a) renin-angiotensin system inhibitor(s) on (a) renal disease(s), comprising as an effective ingredient a prostaglandin I derivative represented by the Formula (I):



[wherein R^1 is

(A) COOR^2 , wherein R^2 is

hydrogen or a pharmaceutically acceptable cation,

2) $\text{C}_1\text{-C}_{12}$ straight alkyl or $\text{C}_3\text{-C}_{14}$ branched alkyl,

Z-R^3 , wherein Z is covalent bond, or straight or branched alkylene represented by C_tH_{2t} wherein t is an integer of 1 to 6, R^3 is $\text{C}_3\text{-C}_{12}$ cycloalkyl or $\text{C}_3\text{-C}_{12}$ cycloalkyl substituted with 1 to 3 R^4 (s) wherein R^4 is hydrogen or $\text{C}_1\text{-C}_5$ alkyl,

$\text{-(CH}_2\text{CH}_2\text{O)}_n\text{CH}_3$, wherein n is an integer of 1 to 5,

-Z-Ar^1 , wherein Z represents the same meanings described above, Ar^1 is phenyl, α -naphthyl, β -naphthyl, 2-pyridyl, 3-pyridyl, 4-pyridyl, α -furyl, β -furyl, α -thienyl, β -thienyl or substituted phenyl (wherein the substituent(s) is(are) at least one of chlorine, bromine, fluorine, iodine, trifluoromethyl, $\text{C}_1\text{-C}_4$ alkyl, nitro, cyano, methoxy, phenyl, phenoxy, p-acetamidobenzamide, $\text{-CH=N-NH-C(=O)-NH}_2$,

-NH-C(=O)-Ph , -NH-C(=O)-CH_3 and -NH-C(=O)-NH_2),

$\text{-C}_t\text{H}_{2t}\text{COOR}^4$, wherein C_tH_{2t} and R^4 represent the same meanings as described above,

$\text{-C}_t\text{H}_{2t}\text{N(R}^4)_2$, wherein C_tH_{2t} and R^4 represent the same meanings as described above,

-CH(R⁵)-C(=O)-R⁶, wherein R⁵ is hydrogen or benzoyl, and R⁶ is phenyl, p-bromophenyl, p-chlorophenyl, p-biphenyl, p-nitrophenyl, p-benzamidephenyl or 2-naphthyl,

-C_pH_{2p}-W-R⁷, wherein W is -CH=CH-, -CH=CR⁷- or -C≡C-, wherein R⁷ is hydrogen, C₁-C₃₀ straight or branched alkyl or C₁-C₃₀ aralkyl, p is an integer of 1 to 5, or

10) -CH(CH₂OR⁸)₂, wherein R⁸ is C₁-C₃₀ alkyl or acyl,

(B) -CH₂OH,

(C) -C(=O)N(R⁹)₂, wherein R⁹ is hydrogen, C₁-C₁₂ straight alkyl, C₃-C₁₂ branched alkyl, C₃-C₁₂ cycloalkyl, C₄-C₁₃ cycloalkylalkylene, phenyl, substituted phenyl (wherein the definitions of the substituent(s) are the same as those described in (A) 5) mentioned above), C₇-C₁₂ aralkyl or -SO₂R¹⁰ wherein R¹⁰ is C₁-C₁₀ alkyl, C₃-C₁₂ cycloalkyl, phenyl, substituted phenyl (wherein the definition(s) of the substituent(s) is(are) the same as those described in (A) 5) mentioned above), or C₇-C₁₂ aralkyl, wherein the two R⁹'s may be the same or different, with the proviso that when one of them is -SO₂R¹⁰, the other R⁹ is not -SO₂R¹⁰, or

(D) -CH₂OTHP (wherein THP is tetrahydropyranyl),

A is

-(CH₂)_m-,

-CH=CH-CH₂-,

-CH₂-CH=CH-,

-CH₂-O-CH₂-,

-CH=CH-,

-O-CH₂- or

7) -C≡C-, wherein m is an integer of 1 to 3,

Y is hydrogen, C₁-C₄ alkyl, chlorine, bromine, fluorine, formyl, methoxy or nitro,

B is -X-C(R¹¹)(R¹²)OR¹³, wherein R¹¹ is hydrogen or C₁-C₄ alkyl, R¹³ is hydrogen, C₁-C₁₄ acyl, C₆-C₁₅ aroyl, tetrahydropyranyl, tetrahydrofuranyl, 1-ethoxyethyl or t-butyl,

X is

-CH₂-CH₂-

-CH=CH- or

-C≡C-,

R¹² is

C₁-C₁₂ straight alkyl, C₃-C₁₄ branched alkyl,

-Z-Ar², wherein Z represents the same meanings as described above, Ar² is phenyl, α-naphthyl, β-naphthyl, or phenyl substituted with at least one of chlorine, bromine, fluorine, iodine, trifluoromethyl, C₁-C₄ alkyl, nitro, cyano, methoxy, phenyl and phenoxy,

-C₁H_{2t}OR¹⁴, wherein C₁H_{2t} represents the same meanings as described above, R¹⁴ is C₁-C₆ straight alkyl, C₃-C₆ branched alkyl, phenyl, phenyl substituted with at least one of chlorine, bromine, fluorine, iodine, trifluoromethyl, C₁-C₄ alkyl, nitro, cyano, methoxy, phenyl or phenoxy-substituted phenyl, cyclopentyl, cyclohexyl, cyclopentyl substituted with 1 to 4 C₁-C₄ straight alkyl and cyclohexyl substituted with 1 to 4 C₁-C₄ straight alkyl,

-Z-R³, wherein Z and R³ represent the same meanings as mentioned above,

-C₁H_{2t}-CH=C(R¹⁵)R¹⁶, wherein C₁H_{2t} represents the same meanings as mentioned above, R¹⁵ and R¹⁶ represent hydrogen, methyl, ethyl, propyl or butyl, or

6) -C_uH_{2u}-C≡C-R¹⁷, wherein u is an integer of 1 to 7, C_uH_{2u} is straight or branched alkylene, and R¹⁷ is C₁-C₆ straight alkyl,

E is hydrogen or -OR¹⁸, wherein R¹⁸ is C₁-C₁₂ acyl, C₇-C₁₅ aroyl or R² (wherein R² represents the same meanings as described above),

said formula includes d-isomers, l-isomers and racemic compounds].

2. (Original) The enhancing agent according to claim 1, wherein in said Formula (I),

R¹ is COOR²,

wherein R² is hydrogen or a pharmaceutically acceptable cation,

A is

1) -(CH₂)_m-

2) -CH₂-CH=CH-

wherein m is an integer of 1 to 3,

Y is hydrogen,

B is $-X-C(R^{11})(R^{12})OR^{13}$,

wherein R^{11} and R^{13} is hydrogen, X is

1) $-CH=CH-$

2) $-C\equiv C-$,

R^{12} is

1) $-Z-Ar^2$

wherein Z is covalent bond, or straight or branched alkylene represented by C_tH_{2t} , wherein t is an integer of 1 to 6, Ar^2 is phenyl, α -naphthyl, β -naphthyl, or phenyl substituted with at least one of chlorine, bromine, fluorine, iodine, trifluoromethyl, C_1 - C_4 alkyl, nitro, cyano, methoxy, phenyl and phenoxy, or

2) $-Z-R^3$

wherein Z represents the same meanings as described above, R^3 is C_3 - C_{12} cycloalkyl, or

3) $-C_uH_{2u}-C\equiv C-R^{17}$

wherein u is an integer of 1 to 7, C_uH_{2u} is straight or branched alkylene, and R^{17} is C_1 - C_6 straight alkyl,

said formula includes d-isomers, l-isomers and racemic compounds.

3. (Currently Amended) The enhancing agent according to claim 1, wherein in said Formula (I), R^1 is $COOR^2$, and wherein R^2 is hydrogen or a pharmaceutically acceptable cation,

A is $-(CH_2)_m-$, wherein m is an integer of 1 to 3,

Y is hydrogen,

B is $-X-C(R^{11})(R^{12})OR^{13}$, wherein R^{11} and R^{13} is hydrogen,

X is $-CH=CH-$,

R^{12} is $-C_uH_{2u}-C\equiv C-R^{17}$, wherein u is an integer of 1 to 7, C_uH_{2u} is straight or branched alkylene, and R^{17} is C_1 - C_6 straight alkyl,

E is hydrogen or -OR¹⁸, wherein R¹⁸ is R² (wherein R² represents the same meanings as described above),

said formula includes d-isomers, l-isomers and racemic compounds.

4. (Currently Amended) The enhancing agent according to claim 1, wherein said prostaglandin I derivative is beraprost or a pharmaceutically acceptable salt or ester thereof.

5. (Currently Amended) The enhancing agent according to ~~any one of claims~~ claim 1 to 4, wherein said renin-angiotensin system inhibitor is an ACE inhibitor.

6. (Original) The enhancing agent according to claim 5, wherein said ACE inhibitor is selected from the group consisting of enalapril maleate, alacepril, delapril, ramipril, captopril, lisinopril, benazepril hydrochloride, libenzapril, quinaprilat, imidapril hydrochloride, zofenopril calcium, fosinopril sodium, cilazapril, temocapril hydrochloride, spirapril hydrochloride, perindopril erbumine, moexipril hydrochloride, trandolapril, ceronapril hydrate, utibapril, omapatrilat, Sampatrilat, and their pharmaceutically acceptable salts.

7. (Currently Amended) The enhancing agent according to ~~any one of claims~~ claim 1 to 4, wherein said renin-angiotensin system inhibitory substance is a compound having antagonistic action against angiotensin II receptor.

8. (Original) The enhancing agent according to claim 7, wherein said compound having antagonistic action against angiotensin II receptor is selected from the group consisting of losartan, eprosartan, candesartan cilexetil, valsartan, telmisartan, irbesartan, tasosartan, olmesartan medoxomil, EXP-3174, zolasartan, saprisartan, elisartan potassium, ripisartan, milfasartan, forasartan, embusartan, fonsartan, E4177, YM358, ICI-D8731, TAK-536, CL-329167, pomisartan, candesartan, and their pharmaceutically acceptable salts.

9. (Original) The enhancing agent according to claim 8, wherein said compound having antagonistic action against angiotensin II receptor is selected from the group consisting of losartan, eprosartan, candesartan cilexetil, valsartan, telmisartan, irbesartan, tasosartan, olmesartan medoxomil, EXP-3174, zolasartan, saprisartan, embusartan, candesartan, and their pharmaceutically acceptable salts.

10. (Currently Amended) The enhancing agent according to ~~any one of claims~~ claim 1 to 9, wherein said renal disease is diabetic nephropathy, glomerulonephritis, interstitial nephritis, acute renal failure, or chronic renal failure.

11. (Original) The enhancing agent according to claim 9, wherein said renal disease is chronic renal failure.
12. (Currently Amended) The enhancing agent according to ~~any one of claims claim 1 to 11,~~ wherein said effect of administering renin-angiotensin system inhibitor is ~~the effect to suppress suppression of an~~ elevation of serum creatinine with time during said renal disease(s).
13. (Currently Amended) The enhancing agent according to ~~any one of claims claim 1 to 11,~~ wherein said effect of administering renin-angiotensin system inhibitory substance is ~~the effect to suppress suppression of a~~ sequential decrease in the reciprocal of serum creatinine with time.
14. (Currently Amended) The enhancing agent according to ~~any one of claims claim 1 to 11,~~ wherein said effect of administering renin-angiotensin system inhibitor is ~~the effect to suppress suppression of a~~ decrease in the glomerular filtration rate with time during said renal disease(s).
15. (Currently Amended) A therapeutic or prophylactic agent for renal disease, comprising as effective ingredients the enhancing agent according to ~~any one of claims claim 1 to 14~~ and a renin-angiotensin system inhibitor.
16. (Currently Amended) A kit for therapy or prophylaxis for renal diseases, comprising separately the enhancing agent according to ~~any one of claims claim 1 to 14,~~ and a drug containing as an effective ingredient a renin-angiotensin system inhibitor, wherein said kit is for administering the enhancing agent and the renin-angiotensin system inhibitor at the same time or at different times.
17. (Currently Amended) A method for enhancing therapeutic or prophylactic effect of renin-angiotensin system inhibitor on renal disease, comprising administering the enhancing agent according to ~~any one of claims claim 1 to 14~~ to a patient to whom (a) rennin-angiotensin system inhibitor(s) is(are) administered.
18. (Currently Amended) A method for treating or preventing a renal disease, comprising administering said therapeutic or prophylactic agent for renal diseases according to claim 15, ~~or the drugs contained in the kit of therapeutic or prophylactic agents for renal diseases according to claim 16.~~
- 19.-20. (Cancelled)
21. (New) A method for treating or preventing a renal disease comprising administering the drugs contained in the kit of therapeutic or prophylactic agents for renal diseases according to claim 16.